May 17, 2023
The Patent Trial and Appeal Board found Wednesday that two Agilent Technologies Inc. patents on the gene-editing tool CRISPR were invalid, the latest dustup in a legal fight brought by Synthego Corp. over the breakthrough technology.
June 01, 2022
The Patent Trial and Appeal Board has agreed to review whether two Agilent Technologies Inc. patents related to the breakthrough gene-editing technology CRISPR should be invalidated.